K. Park

1.4k total citations
43 papers, 994 citations indexed

About

K. Park is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, K. Park has authored 43 papers receiving a total of 994 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Pulmonary and Respiratory Medicine, 26 papers in Oncology and 12 papers in Surgery. Recurrent topics in K. Park's work include Lung Cancer Treatments and Mutations (24 papers), Lung Cancer Research Studies (9 papers) and Colorectal Cancer Treatments and Studies (8 papers). K. Park is often cited by papers focused on Lung Cancer Treatments and Mutations (24 papers), Lung Cancer Research Studies (9 papers) and Colorectal Cancer Treatments and Studies (8 papers). K. Park collaborates with scholars based in South Korea, United States and China. K. Park's co-authors include Myung‐Ju Ahn, Yong Chan Ahn, Jong‐Mu Sun, Jin Seok Ahn, S.-H. Lee, Wonseok Kang, Young Hyeh Ko, W. S. Kim, Young Mog Shim and Joungho Han and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

K. Park

41 papers receiving 988 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
K. Park South Korea	13	664	482	224	201	196	43	994
Mona Fouad Egypt	16	638 1.0×	278 0.6×	70 0.3×	95 0.5×	157 0.8×	32	896
Keita Kudo Japan	13	1.0k 1.6×	611 1.3×	60 0.3×	122 0.6×	173 0.9×	35	1.3k
L. Kayitalire France	17	745 1.1×	453 0.9×	123 0.5×	173 0.9×	163 0.8×	40	1.1k
Giovanni Randon Italy	16	673 1.0×	361 0.7×	163 0.7×	183 0.9×	140 0.7×	51	915
Ryoji Kato Japan	13	1.2k 1.8×	711 1.5×	65 0.3×	121 0.6×	206 1.1×	24	1.4k
Cathy M. Mojzisik United States	18	582 0.9×	345 0.7×	209 0.9×	346 1.7×	168 0.9×	39	1.2k
James E. Bradof United States	13	547 0.8×	272 0.6×	322 1.4×	80 0.4×	110 0.6×	19	874
Jeltje F. de Vries Netherlands	10	747 1.1×	669 1.4×	62 0.3×	80 0.4×	122 0.6×	15	1.2k
Eleni Timotheadou Greece	17	616 0.9×	222 0.5×	51 0.2×	156 0.8×	303 1.5×	76	1.0k
G. R. Blumenschein United States	18	616 0.9×	516 1.1×	162 0.7×	69 0.3×	300 1.5×	57	1.0k

Countries citing papers authored by K. Park

Since Specialization

Citations

This map shows the geographic impact of K. Park's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Park with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Park more than expected).

Fields of papers citing papers by K. Park

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. Park. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Park. The network helps show where K. Park may publish in the future.

Co-authorship network of co-authors of K. Park

This figure shows the co-authorship network connecting the top 25 collaborators of K. Park. A scholar is included among the top collaborators of K. Park based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. Park. K. Park is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lim, Sung-Nam, Ho Jung An, Kyae Hyung Kim, et al.. (2023). MA13.04 Final Overall Survival Analysis of Osimertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations (KCSG-LU15-09). Journal of Thoracic Oncology. 18(11). S145–S145. 3 indexed citations

Park, Seo‐Young, Jong‐Mu Sun, Yoon‐La Choi, et al.. (2022). Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study. ESMO Open. 7(1). 100385–100385. 32 indexed citations

Park, Seo‐Young, S.T. Kim, Jin Hyoung Kang, et al.. (2020). A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy. Annals of Oncology. 31(10). 1397–1404. 122 indexed citations

Kim, S-B., Bhumsuk Keam, Seong Hoon Shin, et al.. (2020). 928P Phase I dose-expansion (part II) study of ISU104 (a novel anti-ErbB3 monoclonal antibody) alone and combination with cetuximab (CET), in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Annals of Oncology. 31. S667–S668. 3 indexed citations

Jung, Hyun Ae, Seok–Jin Hong, Ji Hoon Park, et al.. (2019). MA19.06 Successful Development of Realtime Automatically Updated Data Warehouse in Health Care (ROOT-S). Journal of Thoracic Oncology. 14(10). S328–S328. 1 indexed citations

Kim, Y., Chul‐Hwan Kim, Hyoyoung Lee, et al.. (2019). OA14.07 Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced NSCLC Treated with Immunotherapy. Journal of Thoracic Oncology. 14(10). S245–S245. 1 indexed citations

Ahn, Myung‐Ju, Seo‐Young Park, Ji Hoon Park, et al.. (2019). MA21.10 Phase II Study of 160mg of Osimertinib in EGFR T790M Positive NSCLC with Brain or Leptomeningeal Metastases Who Progressed on Prior EGFR TKI. Journal of Thoracic Oncology. 14(10). S338–S338. 1 indexed citations

Pathak, Khyatiben V., Derek Cridebring, Denise J. Roe, et al.. (2019). P2.12-14 A Pilot Study of Serial Plasma Metabolomics in Small Cell Lung Cancer Patients. Journal of Thoracic Oncology. 14(10). S817–S818. 1 indexed citations

Sun, Jong‐Mu, Jin Seok Ahn, K. Park, et al.. (2018). OA10.05 An Open-Label, Multicenter, Phase II Single Arm Trial of Osimertinib in NSCLC Patients with Uncommon EGFR Mutation(KCSG-LU15-09). Journal of Thoracic Oncology. 13(10). S344–S344. 12 indexed citations

10.

Park, K., Myung‐Ju Ahn, Min Hee Hong, et al.. (2018). OA10.06 A First-in-Human Phase 1 Trial of the EGFR-cMET Bispecific Antibody JNJ-61186372 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 13(10). S344–S345. 7 indexed citations

11.

Ahn, Jin Seok, H.K. Kim, Yong Chan Ahn, et al.. (2017). Randomized phase ii trial comparing chemoradiotherapy with chemotherapy for completely resected unsuspected N2-positive non-small cell lung cancer. Annals of Oncology. 28. v457–v457. 4 indexed citations

12.

Yoshioka, Hiroshige, K. Azuma, Nobuyuki Yamamoto, et al.. (2015). A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study). Annals of Oncology. 26(10). 2066–2072. 89 indexed citations

13.

Soo, Ross A., D.-W. Kim, K. Park, et al.. (2015). 469P Highly selective c-Met inhibitor tepotinib plus gefitinib is active in Asian patients with c-Met+ NSCLC. Annals of Oncology. 26. ix125–ix125. 3 indexed citations

14.

Lim, Sung Hee, Min Eui Hong, Sung Woo Ahn, et al.. (2015). Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer. European Journal of Cancer. 52. 1–9. 116 indexed citations

15.

Lim, Sung Hee, Jin Yong Lee, H.S. Kim, et al.. (2014). A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer. Annals of Oncology. 26(4). 762–768. 70 indexed citations

16.

Kim, Seung‐Whan, Myung‐Ju Ahn, Jin Seok Ahn, et al.. (2012). Concurrent Thoracic Radiotherapy (TRT) with Either the First Cycle or the Third Cycle of Cisplatin and Etoposide Chemotherapy to Determine the Optimal Timing of TRT for Limited-Disease Small-Cell Lung Cancer. Annals of Oncology. 23. xi30–xi30.

17.

Jun, Hee Jae, Myung‐Ju Ahn, Hyo Song Kim, et al.. (2008). ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. British Journal of Cancer. 99(1). 167–172. 123 indexed citations

18.

Park, K., et al.. (2007). A case of agminated lentiginosis with multiple café-au-lait macules. Clinical and Experimental Dermatology. 32(6). 658–660. 2 indexed citations

19.

Ryoo, Jae Wook, Ji Young Woo, K. Park, et al.. (2001). Investigation of juxtasellar and cerebellopontine angle meningiomas and neurogenic tumours: two-phase helical CT. Neuroradiology. 43(8). 637–643. 5 indexed citations

20.

Lee, K S, et al.. (2000). Primary Tumors and Mediastinal Lymph Nodes After Neoadjuvant Concurrent Chemoradiotherapy of Lung Cancer: Serial CT Findings with Pathologic Correlation. Journal of Computer Assisted Tomography. 24(1). 35–40. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact